



BC Centre for Disease Control  
Provincial Health Services Authority

Communicable Diseases and Immunization Service  
655 West 12th Avenue  
Vancouver, BC V5Z 4R4

Tel 604.707.2548  
Fax 604.707.2515  
[www.bccdc.ca](http://www.bccdc.ca)

**Date: May 28, 2021**

**Administrative Circular: 2021:21**

**ATTN:** Medical Health Officers and Branch Offices  
Public Health Nursing Administrators and Assistant Administrators  
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,  
Part 4 – Biological Products**

## **Part 4 – Biological Products**

### **COVID-19 Vaccines**

#### **COVID-19 mRNA Vaccine BNT162b2 (Pfizer)**

The product page has been revised as follows:

- **Doses and Schedules:**
  - The interval between dose 1 and 2 has been revised to 21 days with additional content to Footnote C to indicate that this is the authorized Health Canada schedule, however, the current interval in BC is based on vaccine supply and operational recommendations as outlined on the [government of BC website](http://www2.gov.bc.ca). As of May 27, 2021, the recommended interval between dose 1 and 2 is 8 weeks.

**Please remove page numbers: 1-5 dated May 20, 2021**  
**Please add new page numbers: 1-5 dated May 28, 2021**

#### **COVID-19 mRNA Vaccine mRNA-1273 (Moderna)**

The product page has been revised as follows:

- **Doses and Schedules:**
  - The interval between dose 1 and 2 has been revised to 28 days with additional content to Footnote D to indicate that this is the authorized Health Canada schedule, however, the current interval in BC is based on vaccine supply and operational recommendations as outlined on the [government of BC website](http://www2.gov.bc.ca). As of May 27, 2021, the recommended interval between dose 1 and 2 is 8 weeks.

**Please remove page numbers: 1-4 dated May 20, 2021**  
**Please add new page numbers: 1-4 dated May 28, 2021**

Page 1 of 2

**COVID-19 Vaccine (ChAdOx1-S [recombinant]) (AstraZeneca/Verity Pharmaceuticals)**

The product page has been revised as follows:

- **Doses and Schedules:**
  - The interval between dose 1 and dose 2 has been revised to 8 to 12 weeks apart.
  - Footnote D has been revised to indicate that the preferred interval is 8 to 12 weeks.
- **Adverse Events:**
  - The onset of most cases of serious blood clots following receipt of the AstraZeneca or COVISHIELD vaccine has been revised to 4 to 28 days.
  - The frequency of Thrombosis with Thrombocytopenia Syndrome following a second dose of vaccine has been added.

**Please remove page numbers:** 1-4 dated May 20, 2021  
**Please add new page numbers:** 1-4 dated May 28, 2021

**COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)**

The product page has been revised as follows:

- **Adverse Events:**
  - The onset of most cases of serious blood clots following receipt of the Janssen vaccine has been revised to 4 to 28 days.

**Please remove page numbers:** 1-4 dated May 20, 2021  
**Please add new page numbers:** 1-4 dated May 28, 2021

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: [stephanie.meier@bccdc.ca](mailto:stephanie.meier@bccdc.ca)).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM  
Medical Director  
Communicable Diseases & Immunization Service  
BC Centre for Disease Control

pc:

Provincial Health Officer  
Dr. Bonnie Henry

Dr. Reka Gustafson  
Vice President, Public Health &  
Wellness, PHSA & Deputy Provincial  
Health Officer

Deputy Provincial Health Officer  
Dr. Martin Lavoie

BC Ministry of Health, Population &  
Public Health Division:

Brian Sagar  
Senior Director Communicable  
Disease, Population and Public Health  
Division

Bernard Achampong  
Executive Director,  
Public Health, Planning and Prevention,  
Population and Public Health Division